Illuminating Biological Dark Matter: Integrating Metagenomics, Synthetic Biology, and AI to Unlock Microbial and Genomic Potential for Therapeutics and Biotechnology

Biological “dark matter,” encompassing uncultured microorganisms and poorly characterized regions of microbial and human genomes, represents a vast and largely untapped resource for therapeutic discovery and sustainable biotechnology. Traditional cultivation-based approaches have accessed only a small fraction of this diversity, limiting innovation in drug development, biomanufacturing, and precision medicine. Recent advances in metagenomics, synthetic biology, proteogenomics, and artificial intelligence (AI) offer powerful tools to overcome these constraints. This study presents a systematic review and quantitative meta-analysis conducted in accordance with PRISMA guidelines. Peer-reviewed literature published between 2000 and 2025 was retrieved from PubMed, Web of Science, Scopus, and Google Scholar. Eligible studies employed function-based, sequencing-based, or single-cell metagenomics; synthetic biology chassis systems; AI- or machine learning–driven bioprocess optimization; proteogenomic integration; HIV-1 genomic surveillance; or gut microbiota interventions. Effect sizes were extracted and synthesized using random-effects models, with heterogeneity, publication bias, and sensitivity analyses performed to ensure robustness. Meta-analytic synthesis revealed that metagenomic approaches significantly enhance the discovery of structurally novel and bioactive natural products compared with conventional methods. Engineered microbial chassis, particularly yeast and cyanobacteria, demonstrated consistent improvements in biomass accumulation and metabolite yield. AI-driven models achieved high predictive accuracy across bioprocessing applications, while proteogenomic integration revealed reproducible genotype–phenotype associations in cancer. Microbiome-based interventions showed moderate but consistent improvements in microbial diversity and metabolic function. Collectively, the findings demonstrate that integrating metagenomics, synthetic biology, proteogenomics, and AI enables scalable, reproducible, and functionally relevant exploration of biological dark matter. This convergence provides a robust framework for advancing therapeutic innovation, sustainable biotechnology, and precision medicine